Project Grant R03CA308472
Award Date 5/1/26
Completion Date 4/30/28
Dollars Obligated $166K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of North Carolina at Chapel Hill $384,630 under the Cancer Biology Research program (CFDA 93.396) on April 10, 2026, for a project titled "Identifying Immune-Mediated Mechanisms of RAS Inhibitor Efficacy and Resistance in Pancreatic Cancer." The award, with a completion date of March 31, 2027, funds research designed to elucidate how tumor-immune microenvironment remodeling contributes to the...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York a $682,673 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective May 1, 2026, with completion targeted for April 30, 2031. This five-year award supports research into the adaptation and evolution of resistance to pan-RAS inhibition in pancreatic ductal adenocarcinoma (PDAC), a disease that claims over 52,000 lives annually in the United...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $375,150 to The Regents of the University of California, San Francisco under the Cancer Treatment Research program (CFDA 93.395) to fund a five-year research initiative (September 1, 2025 – August 31, 2030). The research addresses innate resistance mechanisms to KRAS inhibitors in cancer treatment, focusing on the role of the RhoA-ROCK-Myosin IIA cytoskeletal axis in promoting drug-tolerant persister...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh a $657,776 Project Grant under the Cancer Treatment Research program (CFDA 93.395) beginning August 1, 2025, and extending through May 31, 2030. This award supports the development of highly tumor-selective pan RAS inactivators to address oncogenic RAS-driven cancers, which account for approximately 46% of all human malignancies. The project addresses a significant clinical challenge: while...
- Federal Grant Award Summary New York University School of Medicine received a $435,827 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective June 4, 2025, with completion targeted for May 31, 2027. The grant supports research entitled "Exploiting Synthetic Lethality to Enhance KRAS Inhibitor Therapy of Cancer," which investigates combination therapeutic strategies to overcome intrinsic and emergent resistance to...
- Federal Project Grant Award Summary The National Cancer Institute awarded The University of Texas Health Science Center at San Antonio a $609,846 Project Grant effective April 1, 2026, through March 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). This award funds research targeting mucin-type O-glycosylation as a novel regulatory mechanism in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC). The research addresses the critical clinical...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $627,371 project grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded on June 23, 2025, with an expected completion date of May 31, 2030. This award supports research focused on overcoming treatment resistance in estrogen receptor-positive (ER+) breast cancer through targeted degradation of cyclin-dependent kinases 4 and 6 (CDK4/6). The...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $596,501 to The University of Texas Southwestern Medical Center on June 20, 2026, under the Cancer Biology Research program (CFDA 93.396). The award funds fundamental research investigating the molecular mechanisms of translocation renal cell carcinoma (TRCC), a rare and aggressive pediatric kidney cancer subtype characterized by chromosomal translocations of the microphtalmia transcription...
- Federal Grant Award Summary Duke University received a $411,152 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective September 5, 2025, with a completion date of August 31, 2027. This research initiative addresses the identification and validation of noncovalent protein interactions associated with mutant KRAS (MKRAS) inhibitors, building upon recent advances in KRAS G12C-targeted therapeutics that have achieved FDA...
- Federal Grant Award Summary The National Cancer Institute awarded a $404,972 Project Grant to The University of Texas Health Science Center at San Antonio under the Cancer Biology Research program (CFDA 93.396) for a two-year project period beginning August 1, 2025 and concluding July 31, 2027. This award supports fundamental research investigating ribosomal ribonucleic acid (rRNA) modification, ribosome composition, and specialized translation mechanisms in glioblastoma, the most common and...